Pacira Biosciences Inc expected to post earnings of 71 cents a share - Earnings Preview

Pacira Biosciences

01/08/2025 22:32

Pacira Biosciences Inc PCRX.OQ PCRX.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2025

The Brisbane California California-based  company is expected to report a 2.8% increase in revenue to $183.025 million from $178.02 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Pacira Biosciences Inc is for earnings of 71 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Pacira Biosciences Inc is $30.00, about 29.7% above its last closing price of $21.09

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
0.60
0.60
0.62
Beat
4
Dec. 31 2025
0.88
0.84
0.91
Beat
8.9
Sep. 30 2024
0.75
0.70
0.79
Beat
12.1​
Jun. 30 2024
0.71
0.70
0.89
Beat
27.3
​​Mar. 31 2024
0.61
0.62
0.62
Met
-0.6
Dec. 31 2023
0.88
0.88
0.89
Beat
0.7​
Sep. 30 2023
0.77
0.78
0.72
Missed
-8.2
Jun. 30 2023
0.77
0.76
0.78
Beat
2.9

This summary was machine generated August 1 at 21:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)